DUBLIN--(BUSINESS WIRE)--The "Global Dry Eye Syndrome Drugs Market 2017-2021" report has been added to Research and Markets' offering.
The global dry eye syndrome drugs market to grow at a CAGR of 7.59% during the period 2017-2021.
Global Dry Eye Syndrome Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is Initiatives and programs for supporting patients with ophthalmic disorders. Public awareness about problems related to visual impairment has increased in the last decade because of the increase in the number of government initiatives undertaken by various organizations.
According to the report, one driver in the market is untapped potential in developing countries. Countries such as India, China, and Brazil are some of the most attractive countries for pharmaceutical companies globally. Several factors are responsible for the high growth of the healthcare sector in developing countries. Vast population, growing geriatric population, and lifestyle disorders such as obesity and diabetes that lead to dry eye syndrome are factors expected to drive the market in developing countries.
Further, the report states that one challenge in the market is lack of ophthalmology experts. The lack of trained ophthalmologists who have expertise in treating eye disorders such as dry eyes is one of the key challenges in the market. Although the number of people diagnosed with or prone to eyesight disorders has been on the rise, there are insufficient trained and experienced eye care professionals (ophthalmologists, optometrists, ophthalmic assistants, and ophthalmic nurses) to treat eye disorders. For instance, in Europe, there is just one ophthalmologist for every 8,000 individuals.
Key vendors
- Allergan
- Novartis
- Otsuka Holdings
- Santen Pharmaceutical
Other prominent vendors
- Aerie Pharmaceutical
- Akorn
- Bausch & Lomb
- Johnson & Johnson
- Merck
- MIMETOGEN
- ReGenTree
- Sun Pharmaceutical
- Teva Pharmaceutical
Key Topics Covered:
- Executive Summary
- Scope Of The Report
- Research Methodology
- Introduction
- Market Landscape
- Pipeline Landscape
- Market Segmentation By Product
- Regional Landscape
- Decision Framework
- Drivers And Challenges
- Market Trends
- Vendor Landscape
- Key Vendor Analysis
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/h5rv7d/global_dry_eye